Terms: = Small Cell Lung Cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
1454 results:
1. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
Yamaguchi T; Shimizu J; Matsuzawa R; Watanabe N; Horio Y; Fujiwara Y
BMC Cancer; 2024 Jul; 24(1):842. PubMed ID: 39009968
[TBL] [Abstract] [Full Text] [Related]
2. SHR-A1811 (antibody-drug conjugate) in advanced her2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.
Li Z; Song Z; Hong W; Yang N; Wang Y; Jian H; Liang Z; Hu S; Peng M; Yu Y; Wang Y; Jiao Z; Zhao K; Song K; Li Y; Shi W; Lu S
Signal Transduct Target Ther; 2024 Jul; 9(1):182. PubMed ID: 39004647
[TBL] [Abstract] [Full Text] [Related]
3. A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with her2 mutations.
Wang L; Wu Y; Ren Z; Chu X; Chen J; Liu L; Zhao J; Yu X; Xie M; Su C
Cancer Med; 2024 Jun; 13(12):e7335. PubMed ID: 38923311
[TBL] [Abstract] [Full Text] [Related]
4. Durable Objective Response to Lurbinectedin in small cell Bladder cancer with TP53 Mutation: A Molecular-Directed Strategy.
Moussa MJ; Khandelwal J; Wilson NR; Naik SA; Subbiah V; Campbell MT; Msaouel P; Singh P; Alhalabi O
Curr Oncol; 2024 Jun; 31(6):3342-3349. PubMed ID: 38920737
[TBL] [Abstract] [Full Text] [Related]
5. Ultrasonic-responsive piezoelectric stimulation enhances sonodynamic therapy for her2-positive breast cancer.
Chen Z; Yang L; Yang Z; Wang Z; He W; Zhang W
J Nanobiotechnology; 2024 Jun; 22(1):369. PubMed ID: 38918812
[TBL] [Abstract] [Full Text] [Related]
6. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in her2-positive non-small cell lung cancer.
Shiraishi A; Oh-Hara T; Takahashi Y; Uchibori K; Nishio M; Katayama R
Biochem Biophys Res Commun; 2024 Sep; 725():150255. PubMed ID: 38897043
[TBL] [Abstract] [Full Text] [Related]
7. Prolonged Response to Afatinib and Crizotinib in a Rare Case of
Plomer E; Früh M; Lauber A; Demmer I; Jochum W; Koster KL
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891886
[TBL] [Abstract] [Full Text] [Related]
8. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.
Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H
World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622
[TBL] [Abstract] [Full Text] [Related]
9. PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.
Sarova P; Mosleh B; Zehetmayer S; Oberndorfer F; Widder J; Prosch H; Aigner C; Idzko M; Hoda MA; Gompelmann D
Thorac Cancer; 2024 Jul; 15(20):1598-1606. PubMed ID: 38860475
[TBL] [Abstract] [Full Text] [Related]
10. Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.
de Jager VD; Cajiao Garcia BN; Kuijpers CCHJ; de Bock GH; Maas WJ; Timens W; van Kempen LC; van der Wekken AJ; Schuuring E; Willems SM
Eur J Cancer; 2024 Jul; 205():114125. PubMed ID: 38788285
[TBL] [Abstract] [Full Text] [Related]
11. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-small cell lung Carcinoma with or without Alterations in Oncogenic Drivers.
Somme LB; Chouaid C; Moinard-Butot F; Barbe-Richaud JB; Greillier L; Schott R
BioDrugs; 2024 Jul; 38(4):487-497. PubMed ID: 38767823
[TBL] [Abstract] [Full Text] [Related]
12. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
[No Abstract] [Full Text] [Related]
13. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating her2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT; Meric-Bernstam F; Bardia A; Naito Y; Siena S; Aftimos P; Anderson I; Curigliano G; de Miguel M; Kalra M; Oh DY; Park JO; Postel-Vinay S; Rha SY; Satoh T; Spanggaard I; Michelini F; Smith A; Machado KK; Saura C;
Lancet Oncol; 2024 Jun; 25(6):707-719. PubMed ID: 38710187
[TBL] [Abstract] [Full Text] [Related]
14. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
15. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
[TBL] [Abstract] [Full Text] [Related]
16. An odd dancing couple. Non-small cell lung carcinoma with coexisting EGFR mutation and NTRK-1 translocation: A case report.
Robledano R; Lozano MD
Diagn Cytopathol; 2024 Jul; 52(7):393-396. PubMed ID: 38634549
[TBL] [Abstract] [Full Text] [Related]
17. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathologic and Molecular Characteristics of her2 (erbb2)-Altered Non-small cell lung cancer: Implications for Precision Medicine.
Lee Y; Lee B; Choi YL; Kang DW; Han J
Mod Pathol; 2024 Jun; 37(6):100490. PubMed ID: 38588887
[TBL] [Abstract] [Full Text] [Related]
19. Oncogene-Driven Non-small cell lung cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations.
Huang CY; Jiang N; Shen M; Lai GG; Tan AC; Jain A; Saw SP; Ang MK; Ng QS; Lim DW; Kanesvaran R; Tan EH; Tan WL; Ong BH; Chua KL; Anantham D; Takano AM; Lim KH; Tam WL; Sim NL; Skanderup AJ; Tan DS; Rozen SG
Cancer Res; 2024 Jun; 84(12):2009-2020. PubMed ID: 38587551
[TBL] [Abstract] [Full Text] [Related]
20. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-lung01): primary results of the her2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
[TBL] [Abstract] [Full Text] [Related]
[Next]
